The FDA Group's Insider Newsletter
Subscribe
Sign in
Home
Notes
Archive
Leaderboard
About
FDA News
Latest
Top
Discussions
More OMQ Letters After FDA Inspections? Don't Treat Them as Noise
We're hearing that manufacturers are getting more post-inspection mail from CDER. Here's what the letters actually mean for your next inspection.
May 4
•
The FDA Group
5
2
10 Takeaways from FDA's QMSR Town Hall on Risk-Based Inspections
A quick breakdown of FDA's April town hall on risk-based medical device inspections under the new Compliance Program 7382.850.
Apr 28
•
The FDA Group
15
1
An FDA Warning Letter Came With Pictures
A picture really is worth a thousand words (or in this case, a thousand lines of dense warning letter text).
Mar 24
•
The FDA Group
8
2
What’s Been Happening at the FDA Lately: A Roundup
The past several weeks have been among the most eventful (and chaotic) in recent FDA history. Here's what's been happening.
Mar 18
•
The FDA Group
3
1
A Quick Explainer on FDA's Consolidated Adverse Events Reporting System
The new Adverse Event Monitoring System (AEMS) consolidates decades of fragmented safety reporting. If your company submits adverse event reports to the…
Mar 17
•
The FDA Group
3
1
Industry Pushes for Automatic Post-Inspection Meetings and Faster FDA Response Times
What the January CMC subgroup discussions reveal about potential changes to the Form 483 process amid PDUFA VIII negotiations.
Feb 9
•
The FDA Group
4
1
15 Takeaways from FDA's QMSR Implementation Webinar
RAPS recently hosted an online session on bringing QMSR compliance to life with the FDA’s lead for QMSR implementation. We distilled the practical…
Feb 6
•
The FDA Group
5
2
The FDA Opens Submissions for PreCheck
What the new program means for U.S. drug manufacturing.
Feb 6
•
The FDA Group
5
1
QMSR is Here: What the New Rule and Compliance Program Mean for Device Manufacturers
The FDA's new quality system regulation and compliance program are now in effect. Here's what the new framework looks like, who's most at risk, and what…
Feb 3
•
The FDA Group
3
QSIT is Officially Replaced: What FDA’s New Inspection Program Means Under QMSR
Effective today, FDA medical device inspections will no longer be conducted under the Quality System Inspection Technique (QSIT).
Feb 2
•
The FDA Group
8
3
FDA Drug Reviews Held Steady in 2025 Despite Historic Staffing Losses
A new data study reveals what we've seen firsthand: the FDA isn't slowing down reviews even after trimming its staff significantly.
Jan 8
•
The FDA Group
3
1
FDA Removes a Major Barrier to Using Real-World Evidence in Regulatory Reviews
The agency says it will now evaluate real-world evidence on a case-by-case basis, removing long-standing requirements for identifiable patient-level…
Dec 16, 2025
•
The FDA Group
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
